Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KANK1 antisense RNA 1 (KANK1-AS1) is a human long non-coding RNA transcribed antisense to the KANK1 gene. Like other antisense lncRNAs, it may function in the epigenetic and post-transcriptional regulation of its sense partner gene or others, possibly controlling gene expression, cell proliferation, or apoptosis indirectly[2][3][9]. However, specific biological functions, disease associations, drug interactions, and clinical utility of KANK1-AS1 remain largely uncharacterized in current literature, and no direct evidence exists for its use as a therapeutic target at this time[9]. If you need information about KANK1 (KN motif and ankyrin repeat domains 1), the protein-coding gene, or its roles in cancer and cell biology, please clarify, as those aspects are well-documented and distinct from the antisense non-coding RNA[1][4][7][8][10].
Not applicable. No drugs with a known mechanism of action targeting KANK1-AS1 are documented
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KANK1 antisense RNA 1 (KANK1-AS1).